This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-02. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
=== Alkaline lysis === The most common method is alkaline lysis, which involves the use of a high concentration of a basic solution, such as sodium hydroxide, to lyse the bacterial cells. When bacteria are lysed under alkaline conditions (pH 12.0–12.5) both chromosomal DNA and protein are denatured; the plasmid DNA however, remains stable. Some scientists reduce the concentration of NaOH used to 0.1M in order to reduce the occurrence of ssDNA. After the addition of acetate-containing neutralization buffer to lower the pH to around 7, the large and less supercoiled chromosomal DNA and proteins form large complexes and precipitate; but the small bacterial DNA plasmids stay in solution.
In addition it yielded interesting data in terms of who are the main downloaders of the AIDA program, and has also provided technical (computer) information which aided the release of a freeware upgrade to the software. A second study audited 2,437 separate downloads of the AIDA program. The Internet-based survey methodology was confirmed to be robust and reliable. Over a 7.5-month period (from mid-July 2000 to early March 2001) 2,437 responses were received. During the corresponding period 4,100 actual downloads of the software were independently logged via the same route at the AIDA Website — giving a response rate to this audit of 59.4%. Responses were received from participants in 61 countries — although over half of these (n 5 1,533; 62.9%) originated from the United States and United Kingdom. Of these responses 1,361 (55.8%) were received from people with diabetes and 303 (12.4%) from relatives of patients, with fewer responses from doctors, diabetes educators, students, nurses, pharmacists, and other end users. This study has confirmed the feasibility of using the Internet to survey, at no real cost, a large number of medical software downloaders / users. In addition, it yielded up-to-date and interesting data about who are the main downloaders of the AIDA program. A third study surveyed downloaders of a more recent release of the program (AIDA v4.3a). Over a 1-year period (from March 2001 to February 2002) in total 3,864 responses were received.
Aristotle says that the intellect (nous), the ability to think, has no bodily organ (in contrast with other psychological abilities, such as sense-perception and imagination). Aristotle distinguishes between two types of intellect. These are traditionally called the "passive intellect" and the "active (or agent) intellect". He says that the "active (or agent) intellect" is not mixed with the body and suggests that it can exist apart from it. Hence, scholars face the challenge of explaining the relationship between the intellect and the body in Aristotle. According to one interpretation, a person's ability to think (unlike his other psychological abilities) belongs to some incorporeal organ distinct from his body. This would amount to a form of dualism. However, according to some scholars, it would not be a full-fledged Cartesian dualism. This interpretation creates what Robert Pasnau has called the "mind-soul problem" within Aristotelian hylomorphism: if the intellect belongs to an entity distinct from the body, and the soul is the form of the body, then how is the intellect part of the soul? Another interpretation rests on the distinction between the passive intellect and the agent intellect. According to this interpretation, the passive intellect is a property of the body, while the agent intellect is a substance distinct from the body. Some proponents of this interpretation think that each person has his own agent intellect, which presumably separates from the body at death.
Sources: en.wikipedia.org
Subcutaneous fat is the most widely distributed subcutaneous tissue layer. It is composed of adipocytes, which are grouped together in lobules separated by connective tissue. The number of adipocytes varies among different body areas, while their size varies according to the body's nutritional state. It acts as padding and as an energy reserve, as well as providing some minor thermoregulation via insulation. Subcutaneous fat is found just beneath the skin, as opposed to visceral fat, which is found in the peritoneal cavity, and can be measured using body fat calipers to give a rough estimate of total body adiposity.
This activity might explain why kratom can be dangerous when used in combination with other sedatives. Kratom also contains rhynchophylline, a non-competitive NMDA receptor antagonist. Mitragynine is metabolized in humans via phase I and phase II mechanisms with the resulting metabolites excreted in urine. In in vitro experiments, kratom extracts inhibited CYP3A4, CYP2D6, and CYP1A2 enzymes, which results in significant potential for drug interactions.
=== Maps === National Atlas of the United States – official maps from the U.S. Department of the Interior Wikimedia Atlas of the United States Geographic data related to United States at OpenStreetMap "Measure of America" – a variety of mapped information relating to health, education, income, safety and demographics in the United States
Sources: en.wikipedia.org
==== Mycotoxins ==== In April 2014, aflatoxin B1, a known carcinogenic toxin, melamine, and cyanuric acid were all found in various brands of USA pet food imported into Hong Kong. Since 1993, the FDA has confirmed concerns of toxins in feed grade (animal grade) ingredients, yet to date no comprehensive federal regulation exists on mycotoxin testing in feed grade (animal grade) ingredients used to make pet food. In 1997, the Journal of Food Additives and Contaminants established that low levels of various mycotoxins could cause health concerns in pets, and was found in feed grade ingredients. A study published in the Journal of Food Protection in 2001 cited concerns regarding fungi (the source of mycotoxins) in commercial pet foods and warned about the "risk for animal health". In 2006, a study published in the Journal of Agricultural and Food Chemistry confirmed mycotoxins in pet foods around the world and concluded that contamination of mycotoxins in pet foods can lead to chronic effects on the health of pets. In 2007, the International Journal of Food Microbiology published a study that claimed "mycotoxin contamination in pet food poses a serious health threat to pets", and listed them: aflatoxins, ochratoxins, trichothecenes, zearalenone, fumonisins and fusaric acid. A 2008 study published in the Journal of Animal Physiology and Animal Nutrition found high levels of mycotoxins in the raw ingredients used for pet food in Brazil. A 2010 study in the Journal of Mycotoxin Research tested 26 commercial dog foods and found mycotoxins at concerning sub-lethal levels.
Well-being is what is intrinsically good for a person. Also called welfare and quality of life, it is a measure of how well life is going for someone. In the broadest sense, it covers the balance of all positive and negative aspects of a person's life. More narrowly, it refers only to positive degrees and contrasts with ill-being, which denotes negative ones. In this sense, well-being is what egoists typically seek for themselves and altruists aim to enhance in others, serving as a central goal of many individual and societal endeavors. Researchers discuss different types of well-being by how they are measured, who they belong to, and which domain of life they affect. Subjective well-being refers to how a person feels about and evaluates their life. Objective well-being encompasses factors that can be assessed from an external perspective, such as health, income, and security. Individual well-being concerns the quality of life of a particular person, whereas community well-being measures how well a group of people functions and thrives. Forms of well-being belonging to specific domains of life include physical, psychological, emotional, social, and economic well-being. Theories of well-being aim to identify its essential features. Hedonism argues that well-being ultimately depends on the balance of pleasure over pain. Desire theories hold that the satisfaction of desires is the source of well-being. Objective list theories assert that a combination of diverse elements is responsible for well-being.
University of Toronto Libraries Collection: Discovery and Early Development of Insulin, 1920–1925 CBC Digital Archives – Banting, Best, Macleod, Collip: Chasing a Cure for Diabetes Animations of insulin's action in the body at AboutKidsHealth.ca (archived 9 March 2011) Overview of all the structural information available in the PDB for UniProt: P01308 (Insulin) at the PDBe-KB.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.